211096-49-0

Basic information

• Product Name: GSK-CXCR2
• Synonyms: GSK-CXCR2;N-(2-Bromophenyl)-N'-(7-cyano-1H-benzotriazol-4-yl)urea;SB 265610;1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d] [1,2,3]triazol-7-yl)urea
• CAS NO: 211096-49-0
• Molecular Formula: C14H9BrN6O
• Molecular Weight: 357.17
• Mol File: 211096-49-0.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 527 °C at 760 mmHg
• Flash Point: 272.5 °C
• Appearance: white to light brown/
• Density: 1.779 g/cm³
• Storage Temp.: Store at RT
• Solubility: DMSO: soluble15mg/mL, clear
• CAS DataBase Reference: GSK-CXCR2(CAS DataBase Reference)
• NIST Chemistry Reference: GSK-CXCR2(211096-49-0)
• EPA Substance Registry System: GSK-CXCR2(211096-49-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 211096-49-0(Hazardous Substances Data)

Usage

Uses

SB 265610 is an anti-tumor pharmaceutical developed to act as an antagonist to cysteine-amino acid-cysteine (CXC) chemokines receptor 2 antagonist.

Biological Activity

Potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca 2+ mobilization (IC 50 values are 3.4 and 6800 nM respectively). Inhibits CINC-induced chemotaxis and attenuates neutrophil accumulation in inflammatory lung injury in vivo .

Biochem/physiol Actions

SB265610 is a potent and selective CXCR2 chemokine receptor antagonist. It has a Kd = 2.5 nM.

Relevant articles and documents

IL-8 receptor antagonists

This invention relates to novel benzo-2-triazole substituted compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating IL-8, GROα, GROβ, GROγ and NAP-2 mediated diseases.